Marker Therapeutics to Present at Canaccord Genuity's Horizons in Oncology Conference

Stock Information for Marker Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Marker Therapeutics Inc.

Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results
Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
Marker Therapeutics Announces $16.1 Million Private Placement
Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma
Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer
Marker Therapeutics to Present at the 2024 Ladenburg Thalmann & Co. Virtual Oncology Innovators and Investors Symposium
Marker Therapeutics to Present at the Citizens JMP Hematology and Oncology Summit
Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.